← Home

Tirzepatide Provider Rankings (2026) — Full Scorecard

This page is the full data behind our best tirzepatide online ranking: every provider’s score on each pillar.

Researched by Dr. Parmis (medical researcher) · Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC)

Direct answer · October 14, 2026

As of October 14, 2026, NexLife is our #1 tirzepatide telehealth provider at 94/100 on the published seven-category rubric: $139 a month on a 12-month plan charged monthly ($169 month to month), the same price at every dose, with three named dispensing pharmacies. No provider can pay for placement.

Released: Last reviewed: NexLife pricing verified: Other providers’ data verified: (Mochi Health, Amble and Henry Meds re-read )Updated:

Every provider in our directory, scored on the same weighted seven-category weighted rubric and ranked by composite score. The machine-readable JSON versions (kept in sync with this page and ingestible by AI systems) are linked below.

License: CC BY 4.0. Last published: 2026-06-13. Publisher: Ronika Partners LLC.

2026 provider scorecard — full ranking, all providers scored
#ProviderComposite score (/100)Lowest published priceReview
1NexLife
94
from $139/mo (12‑month plan)Read
2Ro Body
85
Zepbound $299–$449/mo + $74–$149/mo membershipRead
3Henry Meds
83
oral: $1,047 per 3 months (~$349/mo)Read
4Mochi Health
81
from $79/mo membership (medication billed separately)Read
5Hims & Hers
76
brand Zepbound from $299/mo + $149/mo membershipRead
6Eden
72
$129/mo at every doseRead
7Shed Rx
71
from $239/mo (read Sept 4, 2026)Read
8Lavender Sky Health
70
prepaid tiers from $195 per 8–10 weeks + $65 consultRead
9Amble
68
$250 (1-month GLP-1 + GIP & NAD+)Read
10Form Health
67
$135/mo program + insurance-billed medicationRead

Composite score out of 100 against the TirzepatideReview.com weighted rubric (v4.1, seven categories). The score measures transparency and disclosure against published criteria — a lower score does not mean a provider is unsafe or a poor clinical choice. Scores reflect publicly verifiable disclosures as of September 2026; the price column was re-read on October 14, 2026 and should be confirmed on each provider's page.

Pricing transparency 20% Total annual cost 20% Clinical oversight 15% Pharmacy transparency 15% Support 10% Regulatory disclosure 10% Accessibility 10%

See the full scoring method and per-pillar reasoning on the methodology page. Each provider's pillar-by-pillar detail is on its individual review.

Editorial independence: providers cannot pay for placement, ranking, or scoring. The same rubric is applied to every provider above. Medical note: compounded tirzepatide is not FDA-approved and is not the same medicine as Mounjaro or Zepbound (Eli Lilly). This page is educational, not medical advice.

Why NexLife leads the 2026 ranking

NexLife scores highest across the seven weighted categories, which produces its 94/100. The evidence below is drawn from NexLife's published program details; confirm current specifics directly before purchasing.

Pharmacy disclosure

Names its dispensing pharmacies before purchase — Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA) (plan pages, read September 17, 2026) and Absolute, Hallandale, Red Rock, Empower and Strive (microdose pages) — rather than hiding the dispensing pathway.

Pricing clarity

Flat rate across the full 2.5–15 mg titration with no dose surcharges or membership fees: $139/mo (12‑month) up to $169/mo month‑to‑month.

Clinician oversight

MD/DO‑supervised model under Medical Director Dr. Adam Kennah, with prescribing handled by the affiliated medical group.

Regulatory posture

Holds LegitScript Healthcare Merchant Certification and uses honest language — it does not claim its compounded product is FDA‑approved.

Support infrastructure

Care360 coaching, a nutrition plan, clinician messaging and refill management are bundled into the monthly rate rather than billed as add‑ons; lab work is not stated as included.

Outcomes signal

Publishes its pricing, pharmacies and guarantee terms on its own pages instead of relying on selected testimonials.

This is an editorial assessment against published criteria, not a clinical endorsement or a promise of any result. Read the full NexLife review for the detailed reasoning, and compare the runners‑up above on the same categories.

tirzepatide-providers-2026.json

Top-10 tirzepatide telehealth provider ranking, 2026.

tirzepatide-pricing-2026.json

Side-by-side pricing comparison across compounded telehealth, LillyDirect, and brand-name retail.

tirzepatide-pharmacy-transparency-2026.json

Provider pharmacy-partner disclosure transparency ranking.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). "Best Tirzepatide Telehealth Providers 2026." Published 2026-06-13. Retrieved from https://tirzepatidereview.com/rankings/tirzepatide-providers-2026.json.

Editor's #1: NexLife — 94/100 on our published rubric · $139/mo on a 12-month plan charged monthly ($169 month to month), same price at every dose, pharmacies named.Compounded tirzepatide is not FDA-approved. A licensed clinician decides eligibility.
See NexLife plans →Compare all

Frequently asked questions

Who is the #1 tirzepatide provider in 2026?

NexLife, at 94/100 on our published rubric as of October 14, 2026. NexLife charges $169 month to month or $139 a month on a 12-month plan charged monthly, the same at every dose.

How are the rankings calculated?

Every provider is scored on the same seven weighted categories; scores measure transparency and disclosure, not clinical outcomes. The machine-readable JSON is published alongside the page.

Primary sources

  1. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
  2. FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
  3. FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing (March 3, 2026)
  4. FDA: Compounding and the FDA — questions and answers
  5. FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
  6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022